Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · biote Corp. (BTMD)

Biote Q3 2026 revenue falls 9.6% to $43.3 million; full-year guidance unchanged

Negative Impact 3 of 5 earnings Written later

Biote reported third-quarter 2026 revenue of $43.3 million, down 9.6% from $48.0 million a year earlier, and net income of $0.6 million, or $0.01 per diluted share, versus $9.2 million, or $0.22, in the prior-year quarter. The company kept its full-year 2026 guidance of revenue above $175 million and adjusted EBITDA above $25 million, and its interim CEO said a recent rise in procedure volume suggests demand is stabilizing, though the return to growth is progressing more slowly than anticipated.

Key points

  • Revenue was $43.3 million, down 9.6% from $48.0 million; procedure revenue fell 15.1% to $28.9 million while dietary supplements revenue grew 7.3% to $12.0 million.
  • Gross profit margin was 67.7% versus 71.8%, primarily due to residual impacts of the voluntary recall in January 2026.
  • Adjusted EBITDA was $5.1 million versus $12.9 million; net income was $0.6 million, or $0.01 per diluted share, versus $0.22 a year earlier.
  • Full-year 2026 revenue (above $175 million) and adjusted EBITDA (above $25 million) outlook remains unchanged from the second-quarter earnings release.

The filing

Companybiote Corp. (BTMD)
Form8-K, current report
Filed with the SECNov 4, 2026, 4:20 PM ET
Accession number0001193125-26-447331

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.